Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

被引：22

作者：

Nakagawa, K ^{[1
]}

Ishizaki, T ^{[1
]}

机构：

[1] Kumamoto Univ, Grad Sch Clin Pharm, Dept Pharmacol & Therapeut, Kumamoto 8620973, Japan

来源：

PHARMACOLOGY & THERAPEUTICS | 2000年 / 86卷 / 01期

关键词：

pharmacogenetics; polymorphism; cytochromes P-450 (CYPs); cardiovascular drugs; cardiovascular diseases; pharmacodynamics;

D O I：

10.1016/S0163-7258(99)00066-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variability in the individual response to drugs may be due either to interindividual variations in the pharmacokinetics of the drugs or to the heterogeneity of the mechanism(s) underlying the diseases, or both. In both cases, genetic heterogeneity is involved in the metabolism of cardiovascular drugs and pathogenesis of inherited cardiovascular disorders. Molecular genetic technologies can now provide sensitive and efficient genetic testing, not only to identify polymorphic drug metabolism genes, but also to identify disease-associated genes for diagnosis and risk stratification of many hereditary cardiovascular diseases. In this review, we discuss the polymorphic metabolism of cardiovascular drugs and the molecular genetics of cardiovascular diseases in relation to the genes determining the responsiveness to a given drug. (C) 2000 Elsevier Science Inc. All rights reserved.

引用

页码：1 / 28

页数：28

共 360 条

[91] Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer [J].

Furuta, T ;

Ohashi, K ;

Kamata, T ;

Takashima, M ;

Kosuge, K ;

Kawasaki, T ;

Hanai, H ;

Kubota, T ;

Ishizaki, T ;

Kaneko, E .

ANNALS OF INTERNAL MEDICINE, 1998, 129 (12) :1027-1030

[92] Molecular therapies for vascular diseases [J].

Gibbons, GH ;

Dzau, VJ .

SCIENCE, 1996, 272 (5262) :689-693

[93]

Gitelman H J, 1966, Trans Assoc Am Physicians, V79, P221

[94]

GOLDRING MB, 1994, OSTEOARTHR CARTIL S1, V2, P33

[95] BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].

GOLDSTEIN, JA ;

DEMORAIS, SMF .

PHARMACOGENETICS, 1994, 4 (06) :285-299

[96] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].

Goldstein, JA ;

Ishizaki, T ;

Chiba, K ;

deMorais, SMF ;

Bell, D ;

Krahn, PM ;

Evans, DAP .

PHARMACOGENETICS, 1997, 7 (01) :59-64

[97]

GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243

[98] PHARMACOGENETIC PHENOTYPING AND GENOTYPING - PRESENT STATUS AND FUTURE POTENTIAL [J].

GONZALEZ, FJ ;

IDLE, JR .

CLINICAL PHARMACOKINETICS, 1994, 26 (01) :59-70

[99]

GONZALEZ FJ, 1996, CYTOCHROMES P450 MET, P183

[100]

GORDON RD, 1970, AUSTRALAS ANN MED, V19, P287

← 5 6 7 8 9 10 11 12 13 14 →